Nature Communications,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: June 24, 2024
Abstract
Immune
checkpoint
blockade
(ICB)
approaches
have
changed
the
therapeutic
landscape
for
many
tumor
types.
However,
half
of
cutaneous
squamous
cell
carcinoma
(cSCC)
patients
remain
unresponsive
or
develop
resistance.
Here,
we
show
that,
during
cSCC
progression
in
male
mice,
cancer
cells
acquire
epithelial/mesenchymal
plasticity
and
change
their
immune
(IC)
ligand
profile
according
to
features,
dictating
IC
pathways
involved
evasion.
Epithelial
cells,
through
PD-1/PD-L1
pathway,
mesenchymal
CTLA-4/CD80
TIGIT/CD155
pathways,
differentially
block
antitumor
responses
determine
response
ICB
therapies.
Accordingly,
anti-PD-L1/TIGIT
combination
is
most
effective
strategy
blocking
growth
cSCCs
that
contain
both
epithelial
cells.
The
expression
E-cadherin/Vimentin/CD80/CD155
proteins
cSCC,
HNSCC
melanoma
patient
samples
predicts
anti-PD-1/PD-L1
therapy.
Collectively,
our
findings
indicate
selection
therapies
should
take
into
account
features
Science Advances,
Journal Year:
2023,
Volume and Issue:
9(28)
Published: July 14, 2023
The
genetic
circuits
that
allow
cancer
cells
to
evade
immune
killing
via
epithelial
mesenchymal
plasticity
remain
poorly
understood.
Here,
we
showed
mesenchymal-like
(Mes)
KPC3
pancreatic
were
more
resistant
cytotoxic
T
lymphocyte
(CTL)-mediated
than
the
parental
epithelial-like
(Epi)
and
used
parallel
genome-wide
CRISPR
screens
assess
molecular
underpinnings
of
this
difference.
Core
CTL-evasion
genes
(such
as
IFN-γ
pathway
components)
clearly
evident
in
both
types.
Moreover,
identified
validated
multiple
Mes-specific
regulators
cytotoxicity,
such
Egfr
Mfge8.
Both
significantly
higher
expressed
Mes
cells,
their
depletion
sensitized
CTL-mediated
killing.
Notably,
secreted
Mfge8
inhibit
proliferation
CD8+
production
TNFα.
Clinically,
increased
expression
was
correlated
with
a
worse
prognosis.
Thus,
use
Egfr-mediated
intrinsic
Mfge8-mediated
extrinsic
mechanisms
facilitate
escape
from
cells.
World Journal of Hepatology,
Journal Year:
2025,
Volume and Issue:
17(2)
Published: Feb. 20, 2025
BACKGROUND
Understanding
the
status
and
function
of
tumor-infiltrating
immune
cells
is
essential
for
improving
immunotherapeutic
effects
predicting
clinical
response
in
human
patients
with
carcinoma.
However,
little
known
about
cells,
corresponding
research
results
hepatocellular
carcinoma
(HCC)
are
limited.
AIM
To
investigate
potential
biomarker
genes
that
important
development
HCC
to
understand
how
cell
subsets
react
throughout
this
process.
METHODS
Using
single-cell
RNA
sequencing
T-cell
receptor
sequencing,
heterogeneity
functions
subpopulations
from
tissue
normal
adjacent
carcinoma,
as
well
their
possible
interactions,
were
analyzed.
RESULTS
Eight
clusters
analyzed
identified
using
bioinformatics,
including
six
typical
major
two
newly
clusters,
among
which
Fc
epsilon
1G+
T
characterized
by
upregulation
1G,
tyrosine
kinase
binding
protein,
delta
constant,
whereas
metallothionein
1E+
proliferated
significantly
tumors.
Differentially
expressed
genes,
such
regulator
cycle,
cysteine
serine
rich
nuclear
protein
1,
SMAD7
1E,
upregulated
tumors
have
biomarkers.
In
association
analysis,
we
inferred
clonal
expansion
characteristics
each
cluster
patients.
CONCLUSION
We
lymphocyte
critical
revealed
amplification
infiltrating
cells.
These
data
provide
valuable
resources
understanding
HCC.
Frontiers in Cell and Developmental Biology,
Journal Year:
2022,
Volume and Issue:
10
Published: Nov. 18, 2022
Epithelial-mesenchymal
plasticity
(EMP)
refers
to
the
ability
of
cells
dynamically
interconvert
between
epithelial
(E)
and
mesenchymal
(M)
phenotypes,
thus
generating
an
array
hybrid
E/M
intermediates
with
mixed
E
M
features.
Recent
findings
have
demonstrated
how
these
rather
than
fully
play
key
roles
in
most
physiological
pathological
processes
involving
EMT.
To
this
regard,
onset
state
coincides
highest
stemness
gene
expression
is
involved
differentiation
either
normal
cancer
stem
cells.
Moreover,
are
responsible
for
wound
healing
create
a
favorable
immunosuppressive
environment
tissue
regeneration.
Nevertheless,
metastatic
process
increasing
survival,
apoptosis
therapy
resistance
The
present
review
aims
describe
main
features
emerging
concepts
regulating
EMP
formation
by
describing
differences
similarities
In
particular,
comprehension
biology
will
surely
advance
our
understanding
their
they
could
be
exploited
improve
regeneration
repair.
Advanced Science,
Journal Year:
2024,
Volume and Issue:
11(30)
Published: June 12, 2024
Metastasis
is
the
biggest
obstacle
to
esophageal
squamous
cell
carcinoma
(ESCC)
treatment.
Single-cell
RNA
sequencing
analyses
are
applied
investigate
lung
metastatic
ESCC
cells
isolated
from
pulmonary
metastasis
mouse
model
at
multiple
timepoints
characterize
early
microenvironment.
A
small
population
of
parental
KYSE30
line
(Cluster
S)
resembling
metastasis-initiating
(MICs)
identified
because
they
survive
and
colonize
sites.
Differential
expression
profile
comparisons
between
Cluster
S
other
subpopulations
a
panel
7
signature
genes
(MIS),
including
CD44
TACSTD2,
represent
MICs
in
ESCC.
Functional
studies
demonstrated
(CD44
Nature Communications,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: June 24, 2024
Abstract
Immune
checkpoint
blockade
(ICB)
approaches
have
changed
the
therapeutic
landscape
for
many
tumor
types.
However,
half
of
cutaneous
squamous
cell
carcinoma
(cSCC)
patients
remain
unresponsive
or
develop
resistance.
Here,
we
show
that,
during
cSCC
progression
in
male
mice,
cancer
cells
acquire
epithelial/mesenchymal
plasticity
and
change
their
immune
(IC)
ligand
profile
according
to
features,
dictating
IC
pathways
involved
evasion.
Epithelial
cells,
through
PD-1/PD-L1
pathway,
mesenchymal
CTLA-4/CD80
TIGIT/CD155
pathways,
differentially
block
antitumor
responses
determine
response
ICB
therapies.
Accordingly,
anti-PD-L1/TIGIT
combination
is
most
effective
strategy
blocking
growth
cSCCs
that
contain
both
epithelial
cells.
The
expression
E-cadherin/Vimentin/CD80/CD155
proteins
cSCC,
HNSCC
melanoma
patient
samples
predicts
anti-PD-1/PD-L1
therapy.
Collectively,
our
findings
indicate
selection
therapies
should
take
into
account
features